OM:INDEX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

InDex Pharmaceuticals Holding

Executive Summary

InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has InDex Pharmaceuticals Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: INDEX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.3%

INDEX

1.3%

SE Pharmaceuticals

0.7%

SE Market


1 Year Return

-1.0%

INDEX

23.8%

SE Pharmaceuticals

16.9%

SE Market

Return vs Industry: INDEX underperformed the Swedish Pharmaceuticals industry which returned 23.4% over the past year.

Return vs Market: INDEX underperformed the Swedish Market which returned 16.2% over the past year.


Shareholder returns

INDEXIndustryMarket
7 Day-1.3%1.3%0.7%
30 Day24.1%6.6%3.5%
90 Day18.7%15.4%16.0%
1 Year-1.0%-1.0%30.0%23.8%18.6%16.9%
3 Year50.1%50.1%54.9%38.3%30.1%16.4%
5 Yearn/a29.5%0.8%43.4%15.0%

Price Volatility Vs. Market

How volatile is InDex Pharmaceuticals Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InDex Pharmaceuticals Holding undervalued compared to its fair value and its price relative to the market?

8.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate INDEX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate INDEX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: INDEX is unprofitable, so we can't compare its PE Ratio to the SE Pharmaceuticals industry average.

PE vs Market: INDEX is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INDEX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: INDEX is overvalued based on its PB Ratio (8.5x) compared to the SE Pharmaceuticals industry average (3.9x).


Next Steps

Future Growth

How is InDex Pharmaceuticals Holding forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

58.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InDex Pharmaceuticals Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has InDex Pharmaceuticals Holding performed over the past 5 years?

-24.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: INDEX is currently unprofitable.

Growing Profit Margin: INDEX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: INDEX is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.

Accelerating Growth: Unable to compare INDEX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INDEX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.2%).


Return on Equity

High ROE: INDEX has a negative Return on Equity (-114.66%), as it is currently unprofitable.


Next Steps

Financial Health

How is InDex Pharmaceuticals Holding's financial position?


Financial Position Analysis

Short Term Liabilities: INDEX's short term assets (SEK107.1M) exceed its short term liabilities (SEK24.8M).

Long Term Liabilities: INDEX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: INDEX is debt free.

Reducing Debt: INDEX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INDEX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: INDEX has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 24.9% each year.


Next Steps

Dividend

What is InDex Pharmaceuticals Holding current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INDEX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INDEX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INDEX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INDEX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INDEX's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.9yrs

Average management tenure


CEO

Peter Zerhouni (48 yo)

5.33yrs

Tenure

kr4,624,000

Compensation

Mr. Peter Zerhouni, M.Sc., BSc has been Chief Executive Officer at InDex Pharmaceuticals Holding AB (publ) Since April 1, 2015. Mr. Zerhouni has been Chief Executive Officer of InDex Pharmaceuticals AB and ...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD528.93K) is above average for companies of similar size in the Swedish market ($USD231.04K).

Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Peter Zerhouni
Chief Executive Officer5.33yrskr4.62m0.079%
SEK 535.5k
Johan Giléus
Chief Financial Officer3.25yrsno data0.045%
SEK 306.0k
Pernilla Sandwall
Chief Operating Officer8.5yrsno data0.031%
SEK 210.4k
Thomas Knittel
Chief Medical Officer8.58yrsno data0.017%
SEK 114.8k

6.9yrs

Average Tenure

56yo

Average Age

Experienced Management: INDEX's management team is seasoned and experienced (6.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lennart Hansson
Director9.58yrskr400.00k0.081%
SEK 550.8k
Hans Wigzell
Member of Scientific Advisory Boardno datano datano data
Uli Hacksell
Independent Director4.58yrskr400.00k0.077%
SEK 520.2k
Stig Pedersen
Independent Director8.58yrskr200.00k0.072%
SEK 489.3k
Christopher Hawkey
Member of Scientific Advisory Boardno datano datano data
Yilmaz Mahshid
Independent Director0.33yrno datano data
Wenche Rolfsen
Independent Chairman9.58yrskr800.00k0.11%
SEK 766.0k
Gunther Hartmann
Member of Scientific Advisory Boardno datano datano data
Markus Neurath
Member of Scientific Advisory Boardno datano datano data
Robert Löfberg
Member of Scientific Advisory Boardno datano datano data
Marlene Forsell
Independent Director0.33yrno datano data

6.6yrs

Average Tenure

66yo

Average Age

Experienced Board: INDEX's board of directors are considered experienced (6.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.1%.


Top Shareholders

Company Information

InDex Pharmaceuticals Holding AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InDex Pharmaceuticals Holding AB (publ)
  • Ticker: INDEX
  • Exchange: OM
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr679.177m
  • Shares outstanding: 88.78m
  • Website: https://www.indexpharma.com

Number of Employees


Location

  • InDex Pharmaceuticals Holding AB (publ)
  • TomtebodavAegen 23a
  • Stockholm
  • Stockholm County
  • 171 77
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INDEXOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKOct 2016

Biography

InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company’s lead drug candidate is Cobitolimod, which ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/10 22:00
End of Day Share Price2020/08/10 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.